Categories: HealthcareNews

Contract Win

DXS INTERNATIONAL PLC

(AQSE: DXSP)

ExpectCare First Commercial Contract

The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its first NHS commercial contract for its leading-edge AI ExpertCare Clinical Decision Support (CDS) solution.

This unique digital solution “automates” the gathering of all “relevant” patient and NICE treatment information to enable the prescribing clinician to conduct all hypertension medicine reviews faster and in accordance with NICE guidelines.

David Immelman, CEO of DXS International plc commented: “This NHS accredited solution is one of the most cost-effective methods for minimising the public health burden with clear measurable return on investment.”  

The Directors of DXS International plc accept responsibility for this announcement.

Contacts:

David Immelman        01252 719800
DXS International plc
www.dxs-systems.com

AQSE Corporate Broker and Corporate Advisor
Hybridan LLP        020 3764 2341
Claire Louise Noyce

Notes to Editors

About DXS:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.

Staff

Recent Posts

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…

13 minutes ago

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

11 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

14 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

14 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

14 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

14 hours ago